IP Library Patent Application 17381511
Patent Application
App. No. 17/381,511

KITS FOR DETECTING HEV NUCLEIC ACID

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/381,511
Abstract

Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of Hepatitis E Virus (HEV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

Claims (43)

1 . A kit for determining the presence or absence of hepatitis E virus (HEV) in a sample, the kit comprising:

(1) an amplification reagent comprising at least two amplification oligomers for amplifying a target region of an HEV target nucleic acid, wherein

(a) at least one amplification oligomer is selected from the group consisting of

(i) an oligomer comprising a target-hybridizing sequence consisting of a sequence that is from about 14 to about 23 contiguous nucleotides contained in the sequence of SEQ ID NO:63 and that includes at least the sequence of SEQ ID NO:26, including RNA equivalents and DNA/RNA chimerics thereof, and

(ii) an oligomer comprising a target-hybridizing sequence consisting of SEQ ID NO:28, including RNA equivalents and DNA/RNA chimerics thereof; and

(b) at least one amplification oligomer is a promoter primer comprising a target-hybridizing sequence consisting of SEQ ID NO:24, SEQ ID NO:45, SEQ ID NO:51, or SEQ ID NO:56, including RNA equivalents and DNA/RNA chimerics thereof and further comprising a promoter sequence joined to the 5′ end of the target hybridizing sequence; and

(2) one or more reagents selected from the group consisting of

(a) a capture probe oligomer comprising a target-hybridizing sequence that is configured to specifically hybridize to an HEV target sequence, wherein the capture probe target-hybridizing sequence is covalently attached to a sequence or moiety that binds to an immobilized probe;

(b) a detectably labeled detection probe oligomer comprising a target-hybridizing sequence that is from about 14 to about 28 nucleotides in length and is configured to specifically hybridize to a target sequence contained within SEQ ID NO:39 or the complement thereof; and

(c) an enzyme reagent comprising a reverse transcriptase and an RNA polymerase.

2 . The kit of claim 1 , wherein the at least one amplification oligomer of (a) comprises a target-hybridizing sequence consisting of SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:65, or SEQ ID NO:66, including RNA equivalents and DNA/RNA chimerics thereof.

3 . The kit of claim 1 , wherein the at least one amplification oligomer of (a) comprises a target-hybridizing sequence consisting of SEQ ID NO:29 or SEQ ID NO:64, including RNA equivalents and DNA/RNA chimerics thereof.

4 . The kit of claim 1 , wherein the at least one amplification oligomer of (a) comprises the target-hybridizing sequence consisting of SEQ ID NO:28, including RNA equivalents and DNA/RNA chimerics thereof.

5 . The kit of claim 4 , wherein the at least one amplification oligomer of (a) comprises a target-hybridizing sequence consisting of SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, or SEQ ID NO:32, including RNA equivalents and DNA/RNA chimerics thereof.

6 . The kit of claim 1 , wherein the at least one amplification oligomer of (b) comprises a target-hybridizing sequence consisting of SEQ ID NO:24 or SEQ ID NO:46, including RNA equivalents and DNA/RNA chimerics thereof.

7 . The kit of claim 1 , wherein the at least one amplification oligomer of (b) comprises a target-hybridizing sequence consisting of SEQ ID NO:56, including RNA equivalents and DNA/RNA chimerics thereof.

8 . The kit of claim 7 , wherein the nucleobase at position 1 of SEQ ID NO:56 is guanine (G).

9 . The kit of claim 1 , wherein the amplification reagent comprises an amplification oligomer as in (a)(i), an amplification oligomer as in (a)(ii), a first amplification oligomer as in (b), and a second amplification oligomer as in (b).

10 . The kit of claim 9 , wherein

the amplification oligomer as in (a)(i) comprises the target-hybridizing sequence consisting of SEQ ID NO: 65, or an RNA equivalent or DNA/RNA chimeric thereof;

the amplification oligomer as in (a)(ii) comprises the target-hybridizing sequence consisting of SEQ ID NO: 29, or an RNA equivalent or DNA/RNA chimeric thereof;

the first amplification oligomer as in (b) comprises the target-hybridizing sequence consisting of SEQ ID NO:24, or an RNA equivalent or DNA/RNA chimeric thereof; and

the second amplification oligomer as in (b) comprises the target-hybridizing sequence consisting of SEQ ID NO:56, or an RNA equivalent or DNA/RNA chimeric thereof.

11 . The kit of claim 1 , wherein the amplification reagent comprises a first amplification oligomer as in (a)(ii), a second amplification oligomer as in (a)(ii), a first amplification oligomer as in (b), and a second amplification oligomer as in (b).

12 . The kit of claim 1 , wherein the amplification reagent comprises a set of first, second, and third amplification oligomers comprising a set of first, second, and third target-hybridizing sequences, respectively, wherein the set of target-hybridizing sequences consists of:

(i) SEQ ID NO:65, SEQ ID NO:29, and SEQ ID NO:24, including RNA equivalents and DNA/RNA chimerics thereof;

(ii) SEQ ID NO:65, SEQ ID NO:29, and SEQ ID NO:56, including RNA equivalents and DNA/RNA chimerics thereof;

(iii) SEQ ID NO:29, SEQ ID NO:24, and SEQ ID NO:56, including RNA equivalents and DNA/RNA chimerics thereof;

(iv) SEQ ID NO:66, SEQ ID NO:24, and SEQ ID NO:56, including RNA equivalents and DNA/RNA chimerics thereof;

(v) SEQ ID NO:65, SEQ ID NO:24, and SEQ ID NO:56, including RNA equivalents and DNA/RNA chimerics thereof; or

(vi) SEQ ID NO:62, SEQ ID NO:29, and SEQ ID NO:56, including RNA equivalents and DNA/RNA chimerics thereof.

13 . The kit of claim 1 , wherein the at least one amplification oligomer of (a) comprises a target-hybridizing sequence consisting of SEQ ID NO:31, SEQ ID NO:30, SEQ ID NO:29, SEQ ID NO:66, SEQ ID NO:65, SEQ ID NO:64, SEQ ID NO:62, SEQ ID NO:35, SEQ ID NO:34, SEQ ID NO:33, or SEQ ID NO:61, including RNA equivalents and DNA/RNA chimerics thereof.

14 . The kit of claim 1 , wherein the capture probe target-hybridizing sequence consists of SEQ ID NO:4 or SEQ ID NO:42, including complements, DNA equivalents, and DNA/RNA chimerics thereof.

15 . The kit of claim 1 , wherein the detection probe target-hybridizing sequence consists of SEQ I NO:55 or SEQ ID NO:67, including complements, DNA equivalents, and DNA/RNA chimerics thereof.

16 . The kit of claim 1 , wherein the detection probe oligomer comprises a label selected from the group consisting of

(a) a chemiluminescent label;

(b) a fluorescent label;

(c) a quencher; and

(d) a combination of two or more of (a), (b), and (c).

17 . The kit of claim 16 , wherein the label is a chemiluminescent acridinium ester (AE) compound linked between two nucleobases of the at least one detection probe oligomer.

18 . The kit of claim 1 , wherein the promoter sequence is a T7 promoter sequence and the RNA polymerase is a T7 RNA polymerase.

19 . The kit of claim 18 , wherein the T7 promoter sequence has the sequence shown in SEQ ID NO:73.

20 . The kit of claim 1 , wherein the reverse transcriptase is an MMLV reverse transcriptase.

Assignments (1)
SECURITY INTEREST Recorded Oct 12, 2021
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 057787/0526 →